HAS has preferentially recommended bivalent vaccines suitable for Omicron, regardless of the vaccine(s) previously administered.

In the absence of data making it possible to compare the bivalent vaccines with each other, the HAS recommended that they can be used interchangeably in the context of the vaccination campaign. It should be noted, however, that for people under 30 eligible for the booster, only the Comirnaty and Comirnaty bivalent Original / Omicron BA.1 and Comirnaty bivalent Original / Omicron BA.4-5 vaccines remain recommended.

HAS considers that the available data make it possible to consider the booster use of the VidPrevtyn Beta and Nuvaxovid vaccines in subjects over 18 years old vaccinated with an mRNA or adenoviral vector vaccine against Covid-19 as an alternative to vaccines with Bivalent mRNAs for people reluctant to this type of vaccine and those who cannot benefit from it (contraindications).

HAS notes that the original monovalent vaccines Spikevax and Comirnaty can continue to be used in primary vaccination.

The HAS recalls that, even in times of lower circulation of the virus, the priority is to protect the most vulnerable through vaccination.

  • Recommendation
  • Europe
  • France
  • booster dose
  • COVID-19